Despite our best efforts, sometimes errors make it into the final newsletter. We’d like to thank Dr. Jonathan Gamze for pointing out the following errors in Volume 3, Number 5 (Substance Abuse, November 2012): 1) Antabuse was listed as available as a 200 mg pill; in fact it is available in a 250 mg pill; 2) Suboxone is a combination of buprenorphine and naloxone, not buprenorphine and naltrexone, as erroneously stated in the report. Our apologies.